Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

BACKGROUND: Efalizumab is a humanised recombinant monoclonal IgG1 antibody for the treatment of moderate-to-severe plaque psoriasis. When treatment discontinuation is necessary, however, some patients may experience inflammatory recurrence of the disease, which can progress to rebound if untreated....

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A, Toth, Darryl, Rosoph, Les
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636659/
https://www.ncbi.nlm.nih.gov/pubmed/17067371
http://dx.doi.org/10.1186/1471-5945-6-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636659/
https://www.ncbi.nlm.nih.gov/pubmed/17067371
http://dx.doi.org/10.1186/1471-5945-6-9

Ejemplares similares